AF
NMRA icon

Allworth Financial’s Neumora Therapeutics NMRA Stock Holding History

Allworth Financial’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-353
Closed -$259 – 4998
2025
Q2 		$259 Buy
+353
New +$267 ﹤0.01% 4274
2025
Q1 		– Sell
-32
Closed -$67 – 4142
2024
Q4 		$67 Buy
+32
New +$384 ﹤0.01% 3860

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Allworth Financial's NMRA Position: Q3 2025 in Review

Allworth Financial sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 353 shares — an estimated $259 sold.

Allworth Financial first reported a position in NMRA in Q4 2024 and held it in 2 quarters. The position peaked at $259 in Q2 2025. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Allworth Financial reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Allworth Financial sold 353 Neumora Therapeutics shares in Q3 2025, an estimated $259.
  • Allworth Financial first reported a position in Neumora Therapeutics in Q4 2024 and held it in 2 quarters.
  • Allworth Financial's Neumora Therapeutics position peaked at $259 in Q2 2025.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Allworth Financial's 13F filing for Q3 2025, filed 2 Dec 2025.